What is the primary indication for a postmenopausal patient prescribed raloxifene?

For a postmenopausal patient prescribed raloxifene, the primary indication is to reduce the risk of osteoporosis. Raloxifene is a selective estrogen receptor modulator (SERM) that mimics the effects of estrogen on bone tissue without some of the risks associated with hormone replacement therapy. It has been shown to help maintain bone density and decrease the incidence of osteoporotic fractures in postmenopausal women, making it an effective option for osteoporosis prevention.

While it is true that raloxifene has been studied for its potential in reducing breast cancer risk, particularly in women who have a family history of the disease or other risk factors, the primary purpose of prescribing it in the context of postmenopausal osteoporosis is its ability to provide skeletal benefits. Other options, such as increasing calcium absorption and improving lung function, are not relevant to the action of raloxifene and are not the focus of its use in this patient population. Raloxifene is not indicated for lung function improvement, and while calcium supplements can aid in bone health, they are not the primary mechanism by which raloxifene works.